The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies

Stat News

24 June 2019 - The FDA made a mistake Friday by approving a new drug called Vyleesi for women with low sexual desire. 

This is what happens when drug regulators lower — nearly to the floor — their own risk-benefit standards just so they can pander to special interests.

More on why FDA should have rejected Vyleesi in a moment. First, let’s deal with the Wall Street repercussions of this bad decision, starting with the inevitable, unsurprising but also undeserved jump in the stock price of Palatin Technologies.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US